520 related articles for article (PubMed ID: 25151012)
1. Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models.
Toren P; Kim S; Cordonnier T; Crafter C; Davies BR; Fazli L; Gleave ME; Zoubeidi A
Eur Urol; 2015 Jun; 67(6):986-990. PubMed ID: 25151012
[TBL] [Abstract][Full Text] [Related]
2. Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer.
Toren P; Kim S; Johnson F; Zoubeidi A
PLoS One; 2016; 11(4):e0152861. PubMed ID: 27046225
[TBL] [Abstract][Full Text] [Related]
3. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
Thomas C; Lamoureux F; Crafter C; Davies BR; Beraldi E; Fazli L; Kim S; Thaper D; Gleave ME; Zoubeidi A
Mol Cancer Ther; 2013 Nov; 12(11):2342-55. PubMed ID: 23966621
[TBL] [Abstract][Full Text] [Related]
4. Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.
Qi W; Morales C; Cooke LS; Johnson B; Somer B; Mahadevan D
Oncotarget; 2015 Dec; 6(39):41976-87. PubMed ID: 26506516
[TBL] [Abstract][Full Text] [Related]
5. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
6. Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer.
Wu H; Zhang L; Gao X; Zhang X; Duan J; You L; Cheng Y; Bian J; Zhu Q; Yang Y
Cancer Lett; 2017 Jan; 385():108-116. PubMed ID: 27815035
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
8. Targeting AR-Beclin 1 complex-modulated growth factor signaling increases the antiandrogen Enzalutamide sensitivity to better suppress the castration-resistant prostate cancer growth.
Zhang M; Sun Y; Meng J; Zhang L; Liang C; Chang C
Cancer Lett; 2019 Feb; 442():483-490. PubMed ID: 30423407
[TBL] [Abstract][Full Text] [Related]
9. Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer.
Chou FJ; Lin C; Tian H; Lin W; You B; Lu J; Sahasrabudhe D; Huang CP; Yang V; Yeh S; Niu Y; Chang C
Cell Death Dis; 2020 Nov; 11(11):942. PubMed ID: 33139720
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.
Shiota M; Bishop JL; Takeuchi A; Nip KM; Cordonnier T; Beraldi E; Kuruma H; Gleave ME; Zoubeidi A
Oncotarget; 2015 Apr; 6(11):9086-98. PubMed ID: 25871401
[TBL] [Abstract][Full Text] [Related]
11. Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.
Yamamoto Y; Loriot Y; Beraldi E; Zhang F; Wyatt AW; Al Nakouzi N; Mo F; Zhou T; Kim Y; Monia BP; MacLeod AR; Fazli L; Wang Y; Collins CC; Zoubeidi A; Gleave M
Clin Cancer Res; 2015 Apr; 21(7):1675-87. PubMed ID: 25634993
[TBL] [Abstract][Full Text] [Related]
12. Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer.
Thaper D; Vahid S; Kaur R; Kumar S; Nouruzi S; Bishop JL; Johansson M; Zoubeidi A
Sci Rep; 2018 Nov; 8(1):17307. PubMed ID: 30470788
[TBL] [Abstract][Full Text] [Related]
13. Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide.
Pilling AB; Hwang C
Prostate; 2019 Aug; 79(11):1347-1359. PubMed ID: 31228231
[TBL] [Abstract][Full Text] [Related]
14. siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer.
Yamamoto Y; Lin PJ; Beraldi E; Zhang F; Kawai Y; Leong J; Katsumi H; Fazli L; Fraser R; Cullis PR; Gleave M
Clin Cancer Res; 2015 Nov; 21(21):4845-55. PubMed ID: 26106075
[TBL] [Abstract][Full Text] [Related]
15. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
[TBL] [Abstract][Full Text] [Related]
16. Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer.
DiPippo VA; Nguyen HM; Brown LG; Olson WC; Vessella RL; Corey E
Prostate; 2016 Feb; 76(3):325-34. PubMed ID: 26585210
[TBL] [Abstract][Full Text] [Related]
17. Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
Lin SJ; Chou FJ; Li L; Lin CY; Yeh S; Chang C
Cancer Lett; 2017 Jul; 398():62-69. PubMed ID: 28373004
[TBL] [Abstract][Full Text] [Related]
18. The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer.
Wang K; Luo J; Yeh S; You B; Meng J; Chang P; Niu Y; Li G; Lu C; Zhu Y; Antonarakis ES; Luo J; Huang CP; Xu W; Chang C
Nat Commun; 2020 Jun; 11(1):2689. PubMed ID: 32483206
[TBL] [Abstract][Full Text] [Related]
19. A phase I dose-escalation study of enzalutamide in combination with theĀ AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer.
Kolinsky MP; Rescigno P; Bianchini D; Zafeiriou Z; Mehra N; Mateo J; Michalarea V; Riisnaes R; Crespo M; Figueiredo I; Miranda S; Nava Rodrigues D; Flohr P; Tunariu N; Banerji U; Ruddle R; Sharp A; Welti J; Lambros M; Carreira S; Raynaud FI; Swales KE; Plymate S; Luo J; Tovey H; Porta N; Slade R; Leonard L; Hall E; de Bono JS
Ann Oncol; 2020 May; 31(5):619-625. PubMed ID: 32205016
[TBL] [Abstract][Full Text] [Related]
20. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
Thamilselvan V; Menon M; Thamilselvan S
Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]